SYM FINANCIAL Corp Takes Position in Danaher Corporation (NYSE:DHR)

SYM FINANCIAL Corp purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,519 shares of the conglomerate's stock, valued at approximately $311,000.

Several other large investors have also modified their holdings of DHR. Geode Capital Management LLC raised its stake in shares of Danaher by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank bought a new position in shares of Danaher during the 4th quarter worth approximately $2,130,740,000. Bank of New York Mellon Corp raised its stake in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. Northern Trust Corp increased its stake in Danaher by 14.3% during the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after purchasing an additional 992,594 shares in the last quarter. Finally, Capital World Investors increased its stake in Danaher by 32.7% during the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. HSBC cut their price target on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. The Goldman Sachs Group cut their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Barclays reiterated an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, TD Cowen increased their price objective on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Transactions at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of NYSE DHR traded up $5.32 during trading on Thursday, hitting $203.21. The company had a trading volume of 7,410,271 shares, compared to its average volume of 3,878,889. The stock has a fifty day simple moving average of $196.19 and a two-hundred day simple moving average of $204.15. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The firm has a market capitalization of $145.51 billion, a price-to-earnings ratio of 43.24, a price-to-earnings-growth ratio of 2.75 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the business earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. On average, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.63%. Danaher's payout ratio is 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.